Montelukast moderately decreased asthma symptoms in children with persistent asthma

Mazur, Lynnette J.
May 2002
ACP Journal Club;May/Jun2002, Vol. 136 Issue 3, p102
Academic Journal
Comments on a study which examined the use of montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged two to fiver years. Outcome measures; Effects of montelukast on children with persistent asthma; Reasons for the difficulty of swallowing for young children.


Related Articles

  • Pranlukast hydrate in the treatment of pediatric bronchial asthma. Shigemi Yoshihara // Pediatric Health, Medicine & Therapeutics;2013, Vol. 4, p55 

    Pranlukast hydrate is a potent, selective, orally active, cysteinyl leukotriene antagonist that binds at the type 1 receptor. It is used as a 10% dry syrup to treat asthma and allergic rhinitis in pediatric patients. In a 4-week, dose-finding study, a dose-dependent improvement in lung function...

  • Montelukast: A Review of its Therapeutic Potential in Asthma in Children 2 to 14 Years of Age. Muijsers, R.B.R.; Noble, S. // Pediatric Drugs;2002, Vol. 4 Issue 2, p123 

    Montelukast is a cysteinyl leukotriene receptor antagonist which is used as a preventive treatment for persistent asthma in patients ≥2 years of age. In children aged 6 to 14 years montelukast (5 mg/day) treatment resulted in a significant increase in FEV (forced expiratory volume in 1...

  • Montelukast in the treatment of asthma. Lambert, Lynn // South African Pharmaceutical Journal;2014, Vol. 81 Issue 1, p22 

    Despite the ongoing development of treatment standards for asthma, many patients who suffer from this chronic disease do not receive optimal care. The emphasis of asthma treatment is to achieve control through an understanding of the pathophysiology and pharmacotherapy of this chronic condition....

  • Eosinophilic tumor in a patient with bronchial asthma receiving pranlukast. Watanabe, Toru; Iinuma, Yasufumi; Naito, Shin-ichi; Nitta, Koju // European Journal of Pediatrics;Feb2007, Vol. 166 Issue 2, p183 

    The article presents a case report of an eosinophilic inguinal tumor and eosinophilia in an eight-year-old boy with bronchial asthma. The tumor disappeared three months after the cessation of pranlukast therapy being undergone by the boy for the asthma. Pranlukast is included among drugs...

  • Ten-year prescription trends of asthma medications in the management of childhood wheeze. Soh, Jian Yi; Ng, Beatrice; Tan, Zeying; Xu, Shuhui; Hing, Wee Chuan; Wu, Tuck Seng; Chan, Yiong Huak; Lee, Bee Wah // Allergy & Asthma Proceedings;Jan/Feb2014, Vol. 35 Issue 1, p1 

    Asthma is the most common chronic disorder of childhood. The aim of this study was to assess prescription trends of asthma medications to provide a measure to evaluate treatment practices and compliance with established international practice guidelines. A retrospective study of data obtained...

  • Pranlukast: A Review of its Use in the Management of Asthma. Keam, Susan J.; Lyseng-Williamson, Katherine A.; Goa, Karen L. // Drugs;2003, Vol. 63 Issue 10, p991 

    Pranlukast (Onon[sup ®], Azlaire[sup ®]), is an orally administered, selective, competitive antagonist of the cysteinyl leukotrienes (LT) C[sub 4], LTD[sub 4] and LTE[sub 4]. It is indicated for the prophylactic treatment of chronic bronchial asthma in paediatric and adult patients. The...

  • Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Lofdahl, Claes-Goran // BMJ: British Medical Journal (International Edition);07/10/99, Vol. 319 Issue 7202, p87 

    Presents information on a study on the ability of montelukast, a leukotriene receptor antagonist, to allow tapering of inhaled corticosteroids in clinically stable asthmatic patients. Participants and methods; Results; Conclusions.

  • Literature reviews. Birnkrant, David J. // Clinical Pediatrics;Dec1997, Vol. 36 Issue 12, p721 

    Presents a summary of the study which tests whether a leukotriene receptor antagonist (ONO-1078) prevents asthma exacerbations during reduction of high-dose inhaled glucocorticoid. Subjects used in the study; Double-blind treatment period; Conclusions; Commentary on administering leukotriene...

  • Leukotriene inhibitors shown to improve asthma patients. Rodgers, Katie // Drug Topics;4/10/95, Vol. 139 Issue 7, p27 

    Reports that leukotriene inhibitors have been shown to improve asthma symptoms and pulmonary functions. Presentation of evidence of zileuton's therapeutic usefulness at the 1995 International Conference of the American Academy of Allergy and Immunology; Improvements noted in patients treated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics